Patent ID: 9198920
Filing Date: 2015-12-01
Classification: A61K,A61P

Abstract:
1. A method of preventing pregnancy in a woman that comprises, during a five week treatment cycle having a treatment interval of four weeks and a rest interval of 1 week; (A) transdermally administering a contraceptively effective amount of a progestin and an estrogen during the treatment interval by successive applications of transdermal hormone delivery devices and (B) transdermally administering low dose progestin and low dose estrogen throughout the rest interval by application of a transdermal hormone delivery device; wherein: the progestin is levonorgestrel; the amount of the progestin delivered during the treatment interval results in an average levonorgestrel serum concentration of at least 750 pg/ml; the amount of the progestin delivered during the rest interval results in an average levonorgestrel serum concentration that is 25% to 75% the amount of the progestin delivered during the treatment interval; the estrogen is ethinyl estradiol; the amount of the estrogen delivered during the treatment interval results in an average ethinyl estradiol serum concentration of at least 15 pg/ml; and the amount of the estrogen delivered during the rest interval results in an average ethinyl estradiol serum concentration that is 25% to 75% the amount of the estrogen delivered during the treatment interval; whereby the woman experiences menstruation with attenuated symptoms of menstruation during the rest interval.